The U.S. Department of Defense's Defense Advanced Research Projects Agency (DARPA) has tapped Tempe, Ariz.-based startup Inanobio Inc. to build an epigenetic sequencer capable of detecting exposure to weapons of mass destruction (WMDs). The four-year contract, valued at up to $5.4 million, is part of a larger DARPA $27.8 million contract awarded to a consortium led by the Icahn School of Medicine at Mount Sinai Health System in New York under the agency's Epigenetic Characterization and Observation (ECHO) program.